This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Frederick A. Davidorf, MD
Columbus, Ohio

Arch Ophthalmol. 1981;99(10):1867.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The history of the management of retrolental fibroplasia (RLF) reflects a paradox of modern medicine: improvement of care in one specialty often results in complex problems in another. Thus, the development of oxygen (O₂) therapy to promote survival in the premature infant has paralleled closely the iatrogeny of RLF.

As the lifesaving benefits of O₂ therapy became known, its use became universally advocated, so by 1948, the American Academy of Pediatrics recommended 40% to 50% O₂ for all premature infants immediately after birth to be continued for a period from 12 hours to as long as one month.¹ Although the first case of RLF was diagnosed by Terry² in 1942, more than a decade was to pass before a causal relationship between O₂ therapy and RLF would be proved in a series of three controlled clinical trials conducted from 1951 to . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?